Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747572 · ClinicalTrials.gov registry record
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
A clinical trial of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- 401
- Enrollment target
- 20
- Study locations
NCT06747572 is a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 401 participants, below the 712-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06747572, a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- 401 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Conditions Studied
Study Locations (20)
California
- Kaiser Permanente - Los Angeles Medical Center - Los Angeles
- UCLA Division of Nephrology - Los Angeles
- Helen Diller Medical Center at Parnassus Heights - San Francisco
Alabama
- Alabama Kidney Research - Alabaster
- University of Alabama at Birmingham- Nephrology Research Clinic - Birmingham
Connecticut
- Nephrology & Hypertension Associates, PC - Middlebury
- Yale Nephrology Clinical Research Clinic - New Haven
Florida
- Nature Coast Clinical Research - Inverness - Inverness
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- Emory School of Medicine - Renal Division - Atlanta
- Renal Associates, LLC - Columbus
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Nephrology - Boston
Minnesota
- University of Minnesota -Health Clinical Research Unit - Minneapolis
- Mayo Clinic - Rochester - Rochester
Illinois
- UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747572
The ClinicalTrials.gov registry entry for NCT06747572 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 712-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (44% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 0 interventions.
NCT06747572 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06747572 about?
NCT06747572 is a clinical study titled "Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease". The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
What is the current status of trial NCT06747572?
This trial is currently active not recruiting. The enrollment target is 401 participants. The study started on 2024-12-19. Estimated completion is 2026-12-31.
What conditions does trial NCT06747572 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Who is sponsoring clinical trial NCT06747572?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747572 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
RECRUITING · NA
-
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
RECRUITING · Phase 2
-
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.